Cargando…
MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment
To overcome the lack of effective pharmacological treatments for high-risk neuroblastoma (HR-NB), the development of novel in vitro and in vivo models that better recapitulate the disease is required. Here, we used an in vitro multiclonal cell model encompassing NB cell differentiation stages, to id...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692293/ https://www.ncbi.nlm.nih.gov/pubmed/33153038 http://dx.doi.org/10.3390/biomedicines8110471 |
_version_ | 1783614477030129664 |
---|---|
author | Garbati, Patrizia Barbieri, Raffaella Cangelosi, Davide Zanon, Carlo Costa, Delfina Eva, Alessandra Thellung, Stefano Calderoni, Matilde Baldini, Francesca Tonini, Gian Paolo Modesto, Paola Florio, Tullio Pagano, Aldo |
author_facet | Garbati, Patrizia Barbieri, Raffaella Cangelosi, Davide Zanon, Carlo Costa, Delfina Eva, Alessandra Thellung, Stefano Calderoni, Matilde Baldini, Francesca Tonini, Gian Paolo Modesto, Paola Florio, Tullio Pagano, Aldo |
author_sort | Garbati, Patrizia |
collection | PubMed |
description | To overcome the lack of effective pharmacological treatments for high-risk neuroblastoma (HR-NB), the development of novel in vitro and in vivo models that better recapitulate the disease is required. Here, we used an in vitro multiclonal cell model encompassing NB cell differentiation stages, to identify potential novel pharmacological targets. This model allowed us to identify, by low-density RT-PCR arrays, two gene sets, one over-expressed during NB cell differentiation, and the other up-regulated in more malignant cells. Challenging two HR-NB gene expression datasets, we found that these two gene sets are related to high and low survival, respectively. Using mouse NB cisplatin-treated xenografts, we identified two genes within the list associated to the malignant stage (MCM2 and carbonic anhydrase 9), whose expression is positively correlated with tumor growth. Thus, we tested their pharmacological targeting as potential therapeutic strategy. We measured mice survival and tumor growth rate after xenografts of human NB treated with cisplatin in the presence of MCM2/carbonic anhydrase 9 inhibitors (ciprofloxacin and acetazolamide). MCM2 or carbonic anhydrase 9 inhibition significantly increased cisplatin activity, supporting their possible testing for NB therapy. |
format | Online Article Text |
id | pubmed-7692293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76922932020-11-28 MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment Garbati, Patrizia Barbieri, Raffaella Cangelosi, Davide Zanon, Carlo Costa, Delfina Eva, Alessandra Thellung, Stefano Calderoni, Matilde Baldini, Francesca Tonini, Gian Paolo Modesto, Paola Florio, Tullio Pagano, Aldo Biomedicines Article To overcome the lack of effective pharmacological treatments for high-risk neuroblastoma (HR-NB), the development of novel in vitro and in vivo models that better recapitulate the disease is required. Here, we used an in vitro multiclonal cell model encompassing NB cell differentiation stages, to identify potential novel pharmacological targets. This model allowed us to identify, by low-density RT-PCR arrays, two gene sets, one over-expressed during NB cell differentiation, and the other up-regulated in more malignant cells. Challenging two HR-NB gene expression datasets, we found that these two gene sets are related to high and low survival, respectively. Using mouse NB cisplatin-treated xenografts, we identified two genes within the list associated to the malignant stage (MCM2 and carbonic anhydrase 9), whose expression is positively correlated with tumor growth. Thus, we tested their pharmacological targeting as potential therapeutic strategy. We measured mice survival and tumor growth rate after xenografts of human NB treated with cisplatin in the presence of MCM2/carbonic anhydrase 9 inhibitors (ciprofloxacin and acetazolamide). MCM2 or carbonic anhydrase 9 inhibition significantly increased cisplatin activity, supporting their possible testing for NB therapy. MDPI 2020-11-03 /pmc/articles/PMC7692293/ /pubmed/33153038 http://dx.doi.org/10.3390/biomedicines8110471 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Garbati, Patrizia Barbieri, Raffaella Cangelosi, Davide Zanon, Carlo Costa, Delfina Eva, Alessandra Thellung, Stefano Calderoni, Matilde Baldini, Francesca Tonini, Gian Paolo Modesto, Paola Florio, Tullio Pagano, Aldo MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment |
title | MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment |
title_full | MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment |
title_fullStr | MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment |
title_full_unstemmed | MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment |
title_short | MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment |
title_sort | mcm2 and carbonic anhydrase 9 are novel potential targets for neuroblastoma pharmacological treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692293/ https://www.ncbi.nlm.nih.gov/pubmed/33153038 http://dx.doi.org/10.3390/biomedicines8110471 |
work_keys_str_mv | AT garbatipatrizia mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT barbieriraffaella mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT cangelosidavide mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT zanoncarlo mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT costadelfina mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT evaalessandra mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT thellungstefano mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT calderonimatilde mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT baldinifrancesca mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT toninigianpaolo mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT modestopaola mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT floriotullio mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment AT paganoaldo mcm2andcarbonicanhydrase9arenovelpotentialtargetsforneuroblastomapharmacologicaltreatment |